Santen to Present Latest Data on Omidenepag Isopropyl at AAO 2021

1 November 12 th, 2021 Santen to Present Latest Data on Omidenepag Isopropyl at AAO 2021 Santen Pharmaceutical Co., Ltd. ( Head Office in Osaka, hereinafter “Santen”) announced today that some publications including EP2 receptor agonist , omidenepag isopropyl , will be presented at the American Academy of Ophthalmology ’s annual meeting (AAO 2021 ; https://www.aao.org/annual- meeting) from November 12th to 15th, 2021. Omidenepag isopropyl has been sold in Japan and Asia since 2018 as EYBELIS Ophthalmic Solution 0.002%, a treatment for glaucoma and ocular hypertension. Santen submitted the New Drug Application in the United States. (PDUFA 1 date: November 19 th, 2021, Development code: STN10117 00). At this conference, some presentations including the outcome of the pivotal studies submitted in U.S. will be conducted. Presentation topics Session # Title PA041 Omidenepag Isopropyl 0.002% vs. Latanoprost 0.005% in Open-angle Glaucoma/Ocular Hypertension: The Phase 3 PEONY Trial PO215 Omidenepag Isopropyl vs. Timolol Maleate for Open-angle Glaucoma/Ocular Hypertension: The Phase 3 Spectrum 4 Trial PO241 Efficacy and Safety of DE-127 vs. Placebo in Mild or Moderate Myopia: The APPLE Study PO007 Safety and Effectiveness of MicroShunt2 Implantation versus Trabeculectomy: 2-year Results from a Randomized, Multicenter Study For abstracts, ple ase see the following link; https://registration.experientevent.com/showaao211/flow /Attendee#!/registrant//ShowItems/ 1 Prescription Drug User Fee Act 2 Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling products in the Americas, Australia, and New Zealand (press release on May 19, 2021; https://www.santen.com/en/news/20210519-1.pdf). 2 Contact: Investor Relations Group Santen Pharmaceutical Co., Ltd. E-mail: [email protected]

The release as fetched from its publisher. santen.com ↗